NASDAQ:NGM NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.54▼$1.5750-Day Range$1.52▼$1.6352-Week Range$0.60▼$4.69Volume2.39 million shsAverage Volume1.47 million shsMarket Capitalization$128.53 millionP/E RatioN/ADividend YieldN/APrice Target$2.53 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends Get NGM Biopharmaceuticals alerts: Email Address NGM Biopharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside64.0% Upside$2.53 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.54Upright™ Environmental ScoreNews Sentiment0.00Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.93) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.66 out of 5 starsMedical Sector488th out of 936 stocksBiotechnology Industry2nd out of 11 stocks 3.0 Analyst's Opinion Consensus RatingNGM Biopharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageNGM Biopharmaceuticals has received no research coverage in the past 90 days.Read more about NGM Biopharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for NGM. Previous Next 0.0 Dividend Strength Dividend YieldNGM Biopharmaceuticals does not currently pay a dividend.Dividend GrowthNGM Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNGM Biopharmaceuticals has received a 75.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for NGM Biopharmaceuticals is -0.54. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for NGM Biopharmaceuticals this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NGM Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders35.90% of the stock of NGM Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.74% of the stock of NGM Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NGM Biopharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NGM Biopharmaceuticals are expected to grow in the coming year, from ($0.93) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NGM Biopharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NGM Biopharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNGM Biopharmaceuticals has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About NGM Biopharmaceuticals Stock (NASDAQ:NGM)NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.Read More Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. NGM Stock News HeadlinesJuly 26 at 8:18 PM | finance.yahoo.comSwedish Growth Companies With High Insider Ownership In July 2024July 26 at 9:52 AM | morningstar.comSino Biopharmaceutical Ltd 01177July 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 25 at 11:00 AM | finance.yahoo.comSwedish Growth Companies With High Insider Ownership And 31% ROEJuly 22, 2024 | benzinga.comXTL Biopharmaceuticals (NASDAQ:XTLB) Stock Quotes, Forecast and News SummaryMay 29, 2024 | finance.yahoo.comMerck to buy eye drug developer for $1.3BMay 23, 2024 | finance.yahoo.comGlobal Ambulatory Surgical Centers Market is Projected to Boost at a Moderate Growth Rate of ~6% by 2030 | DelveInsightMay 22, 2024 | finance.yahoo.comGlobal Infection Prevention and Control Market is Likely to Increase at a Steady Growth Rate of ~6% by 2030 | DelveInsightJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.May 13, 2024 | finance.yahoo.comSwedish Exchange Highlights Three Growth Companies With High Insider OwnershipApril 5, 2024 | finanznachrichten.deNGM Biopharmaceuticals, Inc.: NGM Bio Announces Closing of Tender OfferApril 5, 2024 | globenewswire.comNGM Bio Announces Closing of Tender OfferMarch 19, 2024 | globenewswire.comNGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual MeetingMarch 13, 2024 | businesswire.comNGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGMMarch 12, 2024 | bizjournals.comHow a VC and a biotech founder plan to create a new biotech modelMarch 12, 2024 | msn.comOracle, Dollar General upgraded: Wall Street's top analyst callsMarch 11, 2024 | globenewswire.comNGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | msn.comTD Cowen Downgrades NGM Biopharmaceuticals (NGM)See More Headlines Receive NGM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:NGM CUSIPN/A CIK1426332 Webwww.ngmbio.com Phone(650) 243-5555FaxN/AEmployees138Year Founded1998Price Target and Rating Average Stock Price Target$2.53 High Stock Price Target$3.50 Low Stock Price Target$1.55 Potential Upside/Downside+64.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,380,000.00 Net Margins-3,223.34% Pretax Margin-3,223.34% Return on Equity-77.85% Return on Assets-67.76% Debt Debt-to-Equity RatioN/A Current Ratio7.79 Quick Ratio7.79 Sales & Book Value Annual Sales$4.42 million Price / Sales29.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book0.86Miscellaneous Outstanding Shares83,462,000Free Float53,499,000Market Cap$128.53 million OptionableOptionable Beta1.27 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. William J. Rieflin J.D. (Age 64)Executive Chairman of the Board of Directors Comp: $1.1MDr. David J. Woodhouse Ph.D. (Age 53)CEO & Director Comp: $860.75kMs. Valerie L. Pierce J.D. (Age 61)Senior VP, General Counsel, Secretary & Chief Compliance Officer Comp: $580.75kDr. Hsiao Dee Lieu F.A.C.C. (Age 54)M.D., Chief Medical Officer & Executive VP Comp: $625.75kJean Frederic Viret Ph.D.Chief Financial OfficerMs. Irene PerlichVP, Corporate Controller & Principal Accounting OfficerMr. Daniel Kaplan Ph.D.Chief Scientific OfficerMahi SarafDirector of People & CultureDiana Peng BockusHead of Business DevelopmentArthur Hsu Ph.D.Senior Director & Head of BiologyMore ExecutivesKey CompetitorsLianBioNASDAQ:LIANPHAXIAM TherapeuticsNASDAQ:PHXMPolarityTENASDAQ:PTEIQ9 Meters BiopharmaNASDAQ:NMTRKaleido BiosciencesNASDAQ:KLDOView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 48,708 shares on 5/20/2024Ownership: 0.058%NatixisBought 181,366 shares on 5/14/2024Ownership: 0.217%Vanguard Group Inc.Sold 446,182 shares on 5/10/2024Ownership: 2.785%BNP Paribas Financial MarketsSold 49,259 shares on 5/1/2024Ownership: 0.205%Mirae Asset Global Investments Co. Ltd.Bought 21,169 shares on 5/1/2024Ownership: 0.025%View All Institutional Transactions NGM Stock Analysis - Frequently Asked Questions How were NGM Biopharmaceuticals' earnings last quarter? NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.03. The business earned $18.58 million during the quarter, compared to the consensus estimate of $18.90 million. NGM Biopharmaceuticals had a negative net margin of 3,223.34% and a negative trailing twelve-month return on equity of 77.85%. What is David Woodhouse's approval rating as NGM Biopharmaceuticals' CEO? 3 employees have rated NGM Biopharmaceuticals Chief Executive Officer David Woodhouse on Glassdoor.com. David Woodhouse has an approval rating of 34% among the company's employees. This puts David Woodhouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. When did NGM Biopharmaceuticals IPO? NGM Biopharmaceuticals (NGM) raised $100 million in an IPO on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO. This page (NASDAQ:NGM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NGM Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NGM Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.